Can a new drug stop Ketamine-Induced psychosis?
NCT ID NCT01892189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested whether a single dose of TAK-063 could prevent brain activity changes and psychotic-like symptoms caused by ketamine in 27 healthy adult men. Researchers used brain scans to measure effects. The goal was to understand how TAK-063 works in the brain, not to treat a disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KETAMINE-INDUCED BRAIN ACTIVITY CHANGES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Brain Institute, University of Utah
Salt Lake City, Utah, 84108, United States